Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BAY 59-7939 (Factor Xa Inhibitor) Phase II Low Dose Study in Patients With Atrial Fibrillation

NCT00973323 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00973323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00973323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BAY 59-7939 (Factor Xa Inhibitor) Phase II Low Dose Study in Patients With Atrial Fibrillation
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2005
Completion date
March 31, 2006
Enrollment
100 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation